These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20632895)

  • 41. Aspirin for primary prevention of cardiovascular disease (revisited).
    Med Lett Drugs Ther; 2006 Jul; 48(1238):53. PubMed ID: 16841021
    [No Abstract]   [Full Text] [Related]  

  • 42. Low-dose aspirin for everyone?
    Johns Hopkins Med Lett Health After 50; 2002 Oct; 14(8):4-5. PubMed ID: 12425276
    [No Abstract]   [Full Text] [Related]  

  • 43. A systematic review on the application of cardiovascular risk prediction models in pharmacoeconomics, with a focus on primary prevention.
    Stevanovic J; Postma MJ; Pechlivanoglou P
    Eur J Prev Cardiol; 2012 Aug; 19(2 Suppl):42-53. PubMed ID: 22988567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Aspirin Primary Prevention Conundrum.
    Schamroth Pravda M; Schamroth Pravda N; Beigel Y; Matetzky S; Beigel R
    Isr Med Assoc J; 2020 Jan; 22(1):60-63. PubMed ID: 31927808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk stratification could reduce costs in primary prevention of cardiovascular disease.
    Dalton AR; Bull RJ
    BMJ; 2011 Aug; 343():d4913. PubMed ID: 21831937
    [No Abstract]   [Full Text] [Related]  

  • 46. Caution Regarding Low-Dose Aspirin for Primary Prevention of Cardiovascular Events.
    Rosenberg K
    Am J Nurs; 2019 Aug; 119(8):49. PubMed ID: 31356330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment and prevention of cardiovascular disease by aspirin.
    Hennekens CH
    Drug Saf; 1991; 6(3):166-70. PubMed ID: 2064760
    [No Abstract]   [Full Text] [Related]  

  • 48. Aspirin in primary prevention: USPSTF recommendations.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(3):176. PubMed ID: 20532445
    [No Abstract]   [Full Text] [Related]  

  • 49. On the potential contribution of aspirin to healthy ageing programmes.
    Morgan GP
    Age Ageing; 2016 Mar; 45(2):e1-3. PubMed ID: 22101149
    [No Abstract]   [Full Text] [Related]  

  • 50. The use of cardiovascular risk factor information in practice databases: making the best of patient data.
    Marshall T
    Br J Gen Pract; 2006 Aug; 56(529):600-5. PubMed ID: 16882378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical trials meta-analysis doubting about the position of aspirin in primary prevention of the cardiovascular diseases].
    Hu DY
    Zhonghua Nei Ke Za Zhi; 2009 Oct; 48(10):805. PubMed ID: 20079216
    [No Abstract]   [Full Text] [Related]  

  • 52. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study.
    Marshall T; Rouse A
    BMJ; 2002 Jul; 325(7357):197. PubMed ID: 12142309
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of the cardiologist in the primary prevention of cardiovascular disease with aspirin.
    Verheugt FW
    J Am Coll Cardiol; 2015 Jan; 65(2):122-4. PubMed ID: 25593052
    [No Abstract]   [Full Text] [Related]  

  • 54. Aspirin for primary prevention: what's a clinician to do?
    Psotka MA; Fleischmann KE
    J Gen Intern Med; 2015 Feb; 30(2):147-9. PubMed ID: 25451988
    [No Abstract]   [Full Text] [Related]  

  • 55. [Aspirin and cancer: evidence of a prophylactic effect].
    Algra AM; Nortier JW
    Ned Tijdschr Geneeskd; 2013; 157(17):A5189. PubMed ID: 23614860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aspirin for primary prevention: Is this the end of the road?
    Singal AK; Karthikeyan G
    Indian Heart J; 2019; 71(2):113-117. PubMed ID: 31280821
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The strengths and limitations of the Ukrainian healthcare system.
    Parkhomenko A
    Eur Heart J; 2013 Dec; 34(45):3465-6. PubMed ID: 24446549
    [No Abstract]   [Full Text] [Related]  

  • 58. Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
    Barmanray R; Hamblin PS
    Intern Med J; 2019 Jan; 49(1):133-134. PubMed ID: 30680892
    [No Abstract]   [Full Text] [Related]  

  • 59. [Aspirin in first prevention for cardiovascular disease:present and future].
    Li XY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Nov; 37(11):967-9. PubMed ID: 20137315
    [No Abstract]   [Full Text] [Related]  

  • 60. [Prevention goes astray. Stop subsidizing of drugs for primary prevention when other alternatives are available].
    Melander A; Agren G
    Lakartidningen; 2004 Dec; 101(51-52):4244-5. PubMed ID: 15658594
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.